Algnomics to Present Clinical Data on Anti-Cancer Gene Therapy Orally at AACR 2026

Algnomics, a company specializing in the development of RNA-based gene therapies, announced on March 5 that it will deliver an oral presentation at the American Association for Cancer Research (AACR 2026), which will be held in San Diego, United States, from April 17 to 22.

AACR is considered one of the world’s top three cancer societies, alongside the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO). This international event is attended by research institutions and global pharmaceutical and biotech companies, including major pharmaceutical firms. Algnomics has been selected as an oral presenter to share interim clinical results for its anti-cancer gene therapy "RZ-001" targeting liver cancer. The company will present the first clinical proof-of-concept (POC) data for RNA editing and correction therapies. Through this presentation, Algnomics aims to demonstrate the clinical efficacy and safety of its RNA editing enzyme technology and intends to actively pursue technology commercialization in the global market.

The company’s flagship pipeline, "RZ-001," is an anti-cancer gene therapy with a complex mechanism of action. It targets telomerase mRNA, which is expressed in more than 80% of all cancer cell types, to induce cancer cell death, promote immune cell infiltration, and enhance response rates to immuno-oncology therapies. The product has received clinical trial approvals from both the Korean Ministry of Food and Drug Safety and the United States Food and Drug Administration (FDA). It has also been granted "Fast Track" and "Orphan Drug Designation" status by the FDA for the treatment of primary liver cancer (HCC) and glioblastoma (GBM).

Algnomics is currently conducting a Phase 1b/2a combination clinical trial of RZ-001 and an immuno-oncology therapy in liver cancer patients, with patient enrollment and dosing underway at nine institutions in Korea. The combination drugs, atezolizumab and bevacizumab, are the most widely used first-line therapies for advanced liver cancer, utilized in more than 70% of cases. However, the response rate for standard therapies is known to be only about 20–30%. If RZ-001 combination therapy demonstrates improved clinical efficacy and higher response rates, it is expected to create synergy for commercialization as well.

In addition, because RZ-001 targets telomerase mRNA, which is expressed in over 80% of all cancer cell types, it has the potential to expand its indications to various cancer types with a single therapy.

A company representative stated, "We are pleased to present clinical POC data for our RNA editing and correction therapy at an international conference," adding, "We will accelerate the development of therapeutics for intractable diseases, taking this AACR presentation as an opportunity."

This content was produced with the assistance of AI translation services.